Fostering Access to Innovative Medicines in Indonesia

Washington, D.C. (December 6, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today in response to the September 3, 2012 Indonesian Presidential Decree (76/2012) that grants compulsory licenses on nine innovative biopharmaceutical products:

Value of Innovation in HIV/AIDS Therapy

Backgrounder: Clinical Trials for HIV

Innovative Medicines Help Turn HIV Infection into Chronic Disease

Washington, D.C. (November 29, 2012) — America’s biopharmaceutical research companies are currently developing 73 innovative medicines and vaccines to help the nearly 1.2 million Americans living with HIV infection today, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) released today.

Executive Summary: Value of Innovation in HIV/AIDS Therapy

PhRMA Launches Second Annual China Days

 Washington, DC/Beijing (November 26, 2012) – 

PhRMA Statement on Clinical Trials, Research Collaborations and Washington Post Article

Washington, D.C. (November 26, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today:

Innovation & Adherence: Two Paths to Better Controlling Diabetes

Washington, D.C. (November 13, 2012) — America’s biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the United States affected by diabetes.

Innovation and Adherence Improves Care and Reduces Costs: Diabetes

PhRMA Statement on PCAST Innovation Report

Washington, D.C. (December 3, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on the President’s Council of Advisors on Science and Technology (PCAST) report:

Pages

Subscribe to RSS - Innovation